James W Denham

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4396120/publications.pdf

Version: 2024-02-01

140 papers	8,534 citations	57631 44 h-index	46693 89 g-index
142 all docs	142 docs citations	142 times ranked	8217 citing authors

#	Article	IF	Citations
1	Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology, The, 2005, 6, 659-668.	5.1	876
2	The radiotherapeutic injury â€“ a complex â€˜woundâ€™. Radiotherapy and Oncology, 2002, 63, 129-145.	0.3	518
3	Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions. Journal of Clinical Oncology, 2007, 25, 2420-2425.	0.8	475
4	Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncology, The, 2011, 12, 451-459.	5.1	387
5	Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncology, The, 2005, 6, 841-850.	5.1	351
6	Radiation enteropathyâ€”pathogenesis, treatment and prevention. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 470-479.	8.2	312
7	An Atlas-Based Electron Density Mapping Method for Magnetic Resonance Imaging (MRI)-Alone Treatment Planning and Adaptive MRI-Based Prostate Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, e5-e11.	0.4	275
8	Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). Journal of Clinical Oncology, 2005, 23, 79-87.	0.8	237
9	MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planning. Radiotherapy and Oncology, 2011, 98, 330-334.	0.3	227
10	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncology, The, 2017, 18, 1221-1237.	5.1	226
11	A Multicentre Year-long Randomised Controlled Trial of Exercise Training Targeting Physical Functioning in Men with Prostate Cancer Previously Treated with Androgen Suppression and Radiation from TROG 03.04 RADAR. European Urology, 2014, 65, 856-864.	0.9	170
12	Is there more than one late radiation proctitis syndrome?. Radiotherapy and Oncology, 1999, 51, 43-53.	0.3	147
13	Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases. Medicine and Science in Sports and Exercise, 2018, 50, 393-399.	0.2	142
14	Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?. Radiotherapy and Oncology, 1999, 52, 157-164.	0.3	139
15	Normal tissue effects: reporting and analysis. Seminars in Radiation Oncology, 2003, 13, 189-202.	1.0	127
16	Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncology, The, 2014, 15, 1076-1089.	5.1	121
17	Radiation damage to the gastrointestinal tract: mechanisms, diagnosis, and management. Current Opinion in Supportive and Palliative Care, 2007, 1, 23-29.	0.5	119
18	Bowel injury: current and evolving management strategies. Seminars in Radiation Oncology, 2003, 13, 358-371.	1.0	117

#	Article	IF	Citations
19	A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiotherapy and Oncology, 2001, 60, 113-122.	0.3	106
20	â€œPelvic radiation diseaseâ€: New understanding and new solutions for a new disease in the era of cancer survivorship. Scandinavian Journal of Gastroenterology, 2011, 46, 389-397.	0.6	102
21	Defining pelvic-radiation disease for the survivorship era. Lancet Oncology, The, 2010, 11, 310-312.	5.1	101
22	Radiation-induced changes in cellularity and proliferation in human oral mucosa. International Journal of Radiation Oncology Biology Physics, 2002, 52, 911-917.	0.4	99
23	A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. Radiotherapy and Oncology, 1997, 45, 117-123.	0.3	96
24	Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncology, The, 2008, 9, 1058-1068.	5.1	94
25	Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trialâ€"Trans-Tasman Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2002, 54, 442-449.	0.4	90
26	Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncology, The, 2019, 20, 267-281.	5.1	84
27	Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncology, The, 2012, 13, 189-195.	5.1	79
28	Is it time for a new formalism to categorize normal tissue radiation injury?. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1105-1106.	0.4	73
29	Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics, 2004, 58, 75-80.	0.4	72
30	Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial. Radiotherapy and Oncology, 2009, 90, 400-407.	0.3	70
31	Does the planning doseâ€“volume histogram represent treatment doses in image-guided prostate radiation therapy? Assessment with cone-beam computerised tomography scans. Radiotherapy and Oncology, 2011, 98, 162-168.	0.3	68
32	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncology, The, 2022, 23, 304-316.	5.1	68
33	Underprediction of human skin erythema at low doses per fraction by the linear quadratic model. Radiotherapy and Oncology, 1996, 40, 23-30.	0.3	65
34	The effect, moderators, and mediators of resistance and aerobic exercise on healthâ€related quality of life in older longâ€term survivors of prostate cancer. Cancer, 2015, 121, 2821-2830.	2.0	63
35	Mucosal regeneration during radiotherapy. Radiotherapy and Oncology, 1996, 41, 109-118.	0.3	60
36	Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 223-228.	0.9	58

#	Article	IF	Citations
37	Combined modality therapy for esophageal carcinoma: Preliminary results from a large Australasian multicenter study. International Journal of Radiation Oncology Biology Physics, 1995, 32, 997-1006.	0.4	53
38	TLD extrapolation for skin dose determination in vivo. Radiotherapy and Oncology, 1996, 41, 119-123.	0.3	53
39	Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 2015, 115, 301-307.	0.3	52
40	Tumour innervation and neurosignalling in prostate cancer. Nature Reviews Urology, 2020, 17, 119-130.	1.9	50
41	Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncology, The, 2012, 13, 1260-1270.	5.1	49
42	Prostate-Specific Membrane Antigen Positron Emission Tomographyâ€“Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning. International Journal of Radiation Oncology Biology Physics, 2017, 99, 701-709.	0.4	48
43	Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 693-702.	0.4	48
44	Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiotherapy and Oncology, 2005, 77, 117-125.	0.3	47
45	Do inflammatory processes contribute to radiation induced erythema observed in the skin of humans?. Radiotherapy and Oncology, 1998, 46, 73-82.	0.3	46
46	Treatment-Related Morbidity in Prostate Cancer: AÂComparison of 3-Dimensional Conformal Radiation Therapy With and Without Image Guidance Using Implanted Fiducial Markers. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1018-1023.	0.4	45
47	A magnetic resonance imagingâ€based workflow for planning radiation therapy for prostate cancer. Medical Journal of Australia, 2011, 194, S24-7.	0.8	44
48	Modeling Urinary Dysfunction After External Beam Radiation Therapy of the Prostate Using Bladder Dose-Surface Maps: Evidence of Spatially Variable Response of the Bladder Surface. International Journal of Radiation Oncology Biology Physics, 2017, 97, 420-426.	0.4	43
49	Gleason scoring: a comparison of classical and modified (International Society of Urological) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.3	42
50	Wellbeing during Active Surveillance for localised prostate cancer: A systematic review of psychological morbidity and quality of life. Cancer Treatment Reviews, 2015, 41, 46-60.	3.4	42
51	Dosimetric intercomparison for two Australasian clinical trials using an anthropomorphic phantom. International Journal of Radiation Oncology Biology Physics, 2002, 52, 566-579.	0.4	41
52	Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial. BMC Cancer, 2011, 11, 517.	1.1	40
53	Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiotherapy and Oncology, 2012, 105, 184-192.	0.3	39
54	Breast Edema in Patients Undergoing Breast-Conserving Treatment for Breast Cancer: Assessment via High Frequency Ultrasound. Breast Journal, 2007, 13, 266-273.	0.4	36

#	Article	IF	Citations
55	Quality improvements in prostate radiotherapy: Outcomes and impact of comprehensive quality assurance during the <scp>TROG</scp> 03.04 â€˜<scp>RADAR</scp>â€™ trial. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 247-257.	0.9	36
56	Assuring high quality treatment delivery in clinical trials â€“ Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 â€œRADARâ€•set-up accuracy study. Radiotherapy and Oncology, 2009, 90, 299-306.	0.3	35
57	A Comparison of the Prognostic Value of Early PSA Test-Based Variables Following External Beam Radiotherapy, With or Without Preceding Androgen Deprivation: Analysis of Data From the TROG 96.01 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2011, 79, 385-391.	0.4	34
58	MRI simulation: end-to-end testing for prostate radiation therapy using geometric pelvic MRI phantoms. Physics in Medicine and Biology, 2015, 60, 3097-3109.	1.6	34
59	Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiotherapy and Oncology, 2003, 68, 255-267.	0.3	33
60	Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 2016, 121, 98-102.	0.3	33
61	The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 2003, 68, 113-122.	0.3	32
62	Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer, 2007, 109, 2004-2010.	2.0	32
63	A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer, 2009, 9, 419.	1.1	32
64	Gastrointestinal Dose-Histogram Effects in the Context of Dose-Volumeâ€“Constrained Prostate Radiation Therapy: Analysis of Data From the RADAR Prostate Radiation Therapy Trial. International Journal of Radiation Oncology Biology Physics, 2015, 91, 595-603.	0.4	31
65	Treatment-time-dependence models of early and delayed radiation injury in rat small intestine. International Journal of Radiation Oncology Biology Physics, 2000, 48, 871-887.	0.4	30
66	Statistical-learning strategies generate only modestly performing predictive models for urinary symptoms following external beam radiotherapy of the prostate: A comparison of conventional and machine-learning methods. Medical Physics, 2016, 43, 2040-2052.	1.6	30
67	Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood. Leukemia and Lymphoma, 2002, 43, 2017-2020.	0.6	29
68	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology, 2020, 52, 192-196.	0.3	29
69	Tumor innervation and clinical outcome in pancreatic cancer. Scientific Reports, 2021, 11, 7390.	1.6	29
70	Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancerâ€”toxicity and dose modification: A transtasman radiation oncology group multi-institution study. International Journal of Radiation Oncology Biology Physics, 1995, 31, 305-313.	0.4	26
71	Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Transâ€Tasman Radiation Oncology Group (<scp>TROG</scp>) 03.04 Randomised Androgen Deprivation and Radiotherapy (<scp>RADAR</scp>) randomized controlled trial for locally advanced prostate cancer. BJU International, 2014, 114, 344-353.	1.3	26
72	Androgen Deprivation Therapy for Prostate Cancer Does Not Increase Cardiovascular Mortality in the Long Term. Oncology, 2012, 82, 56-58.	0.9	25

#	Article	IF	Citations
73	Tissue engineering and regenerative medicine in musculoskeletal oncology. Cancer and Metastasis Reviews, 2016, 35, 475-487.	2.7	25
74	Fractionation in prostate cancer â€“ Is it time after all?. Radiotherapy and Oncology, 2010, 96, 1-5.	0.3	24
75	Body composition, fatigue and exercise in patients with prostate cancer undergoing androgenâ€deprivation therapy. BJU International, 2018, 122, 986-993.	1.3	24
76	Why are pretreatment prostateâ€specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?. Cancer, 2009, 115, 4477-4487.	2.0	23
77	Preliminary experience with a combinedâ€modality approach to the management of oesophageal cancer. Medical Journal of Australia, 1988, 148, 9-13.	0.8	23
78	Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trial. Psycho-Oncology, 2014, 23, 524-530.	1.0	22
79	Fast Automatic Multi-atlas Segmentation of the Prostate from 3D MR Images. Lecture Notes in Computer Science, 2011, , 10-21.	1.0	21
80	Urinary symptoms following external beam radiotherapy of the prostate: Doseâ€“symptom correlates with multiple-event and event-count models. Radiotherapy and Oncology, 2015, 117, 277-282.	0.3	21
81	Multiâ€observer contouring of male pelvic anatomy: Highly variable agreement across conventional and emerging structures of interest. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 264-271.	0.9	21
82	Telling Their Stories, Telling Our Stories. Qualitative Health Research, 2007, 17, 428-441.	1.0	20
83	Spatial features of doseâ€“surface maps from deformably-registered plans correlate with late gastrointestinal complications. Physics in Medicine and Biology, 2017, 62, 4118-4139.	1.6	20
84	Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12â€month randomized controlled trial in men with prostate cancer. BJU International, 2018, 121, 194-202.	1.3	20
85	Characterization of prostate cancer using diffusion tensor imaging: A new perspective. European Journal of Radiology, 2019, 110, 112-120.	1.2	20
86	A combined modality approach to the management of oesophageal cancer. European Journal of Surgical Oncology, 1997, 23, 219-223.	0.5	19
87	Decision-making models in the analysis of portal films: A clinical pilot study. Journal of Medical Imaging and Radiation Oncology, 2000, 44, 72-83.	0.6	19
88	Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial. Histopathology, 2020, 77, 284-292.	1.6	19
89	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patientâ€“data Network Meta-analysis from the MARCAP Consortium. European Urology, 2022, 82, 106-114.	0.9	19
90	Normal variation in cutaneous blood content and red blood cell velocity in humans. Physiological Measurement, 1997, 18, 155-170.	1.2	18

#	Article	IF	Citations
91	Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiation Oncology, 2016, 11, 144.	1.2	18
92	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. JAMA Oncology, 2022, 8, e216871.	3.4	18
93	Clinical use of carbon-loaded thermoluminescent dosimeters for skin dose determination. International Journal of Radiation Oncology Biology Physics, 1995, 33, 943-950.	0.4	17
94	PSA response signatures â€“ a powerful new prognostic indicator after radiation for prostate cancer?. Radiotherapy and Oncology, 2009, 90, 382-388.	0.3	17
95	Direct dose to water dosimetry for pretreatment IMRT verification using a modified EPID. Medical Physics, 2011, 38, 6257-6264.	1.6	17
96	Duration of Short-Course Androgen Suppression Therapy and the Risk of Death As a Result of Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 4682-4687.	0.8	17
97	It's time to depolarise the unhelpful PSAâ€¢testing debate and put into practice lessons from the two major international screening trials. Medical Journal of Australia, 2010, 192, 393-396.	0.8	15
98	Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1189-1195.	0.4	15
99	Response of human hair cortical cells to fractionated radiotherapy. Radiotherapy and Oncology, 1997, 43, 289-292.	0.3	13
100	Recognizing False Biochemical Failure Calls After Radiation With or Without Neo-Adjuvant Androgen Deprivation for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 404-411.	0.4	13
101	Radiation induced bowel injury: a neglected problem. Lancet, The, 2013, 382, 2046-2047.	6.3	13
102	Psychological resilience aspects that mediate the depressive effects of urinary incontinence in prostate cancer survivors 10Âyears after treatment with radiation and hormone ablation. Journal of Psychosocial Oncology, 2017, 35, 438-450.	0.6	13
103	Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: Results from the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 2018, 126, 249-256.	0.3	13
104	Extinction of the weakest. International Journal of Radiation Oncology Biology Physics, 2001, 51, 807-819.	0.4	11
105	Voxelâ€based supervised machine learning of peripheral zone prostate cancer using noncontrast multiparametric MRI. Journal of Applied Clinical Medical Physics, 2020, 21, 179-191.	0.8	10
106	Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials. Frontiers in Oncology, 2020, 10, 1174.	1.3	10
107	Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1304-1318.	0.4	9
108	Registering prostate external beam radiotherapy with a boost from high-dose-rate brachytherapy: a comparative evaluation of deformable registration algorithms. Radiation Oncology, 2015, 10, 254.	1.2	8

#	Article	IF	Citations
109	Long-term results of accelerated radiation treatment for advanced head and neck cancer. Radiotherapy and Oncology, 1998, 49, 29-32.	0.3	7
110	Measuring Time to Biochemical Failure in the TROG 96.01 Trial: When Should the Clock Start Ticking?. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1008-1012.	0.4	7
111	Picking the Optimal Duration of Hormonal Therapy in Men With High-Risk and Locally Advanced Prostate Cancer Treated With Radiotherapy. Seminars in Radiation Oncology, 2013, 23, 206-214.	1.0	7
112	MRC RT01: an important trial. Lancet Oncology, The, 2007, 8, 459-460.	5.1	6
113	Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: An exploratory analysis from the <scp>TROG</scp> 03.04 <scp>RADAR</scp> trial. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 248-255.	0.9	6
114	Value of Combined Androgen Blockade in the Neoadjuvant Treatment of Localized Prostate Cancer: The Jury Must Remain Out. Journal of Clinical Oncology, 2010, 28, e445-e446.	0.8	5
115	Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial. Prostate Cancer, 2012, 2012, 1-11.	0.4	5
116	Paradoxical metastatic progression following 3months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiotherapy and Oncology, 2013, 107, 123-128.	0.3	5
117	Technical quality assurance during the <scp>TROG</scp> 03.04 <scp>RADAR</scp> prostate radiotherapy trial: Are the results reflected in observed toxicity rates?. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 99-108.	0.9	5
118	Independent external validation of predictive models for urinary dysfunction following external beam radiotherapy of the prostate: Issues in model development and reporting. Radiotherapy and Oncology, 2016, 120, 339-345.	0.3	5
119	Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials. Radiotherapy and Oncology, 2020, 150, 281-292.	0.3	5
120	A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells. Communications Biology, 2021, 4, 1014.	2.0	5
121	Erythema: Goodbye LQ!. Radiotherapy and Oncology, 1997, 44, 191-193.	0.3	4
122	'When measurements mean action' decision models for portal image review to eliminate systematic set-up errors. Journal of Medical Imaging and Radiation Oncology, 2004, 48, 272-279.	0.6	4
123	Nonrigid correction of interleaving artefacts in pelvic MRI. , 2009, , .		4
124	Thrombin generation as a predictor of radiotherapy induced skin erythema. Radiotherapy and Oncology, 2009, 90, 136-140.	0.3	4
125	Serum procollagen 1 aminoâ€terminal propeptide (<scp>P</scp>1<scp>NP</scp>) in prostate cancer: Pitfalls of its use as an early surrogate marker for bone metastasis. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 497-502.	0.9	4
126	Accumulation of rectum doseâ€volume metrics for prostate external beam radiotherapy combined with brachytherapy: Evaluating deformably registered dose distribution addition using parameterâ€based addition. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 534-542.	0.9	4

#	Article	IF	Citations
127	Hypofractionated versus standard fractionation radiotherapy in early glottic cancer: A retrospective review. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 239-243.	0.7	3
128	Multi-atlas and unsupervised learning approach to perirectal space segmentation in CT images. Australasian Physical and Engineering Sciences in Medicine, 2016, 39, 933-941.	1.4	3
129	External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. Frontiers in Oncology, 2020, 10, 910.	1.3	3
130	Researching Depression in Prostate Cancer Patients: Factors, Timing, and Measures. Journal of Men's Health, 2014, 11, 145-156.	0.1	2
131	Is there a relationship between skin erythema and fatigue in women undergoing irradiation after breast conserving surgery for early breast cancer? A prospective study. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 257-263.	0.7	1
132	An important piece of the localized prostate cancer puzzle?. Nature Reviews Clinical Oncology, 2011, 8, 573-574.	12.5	1
133	A methodology for the analysis of PSA response signatures. Radiotherapy and Oncology, 2011, 98, 198-202.	0.3	1
134	Another form of subgroup to beware. Radiotherapy and Oncology, 2011, 101, 525-526.	0.3	1
135	Multi-atlas and Gaussian Mixture Modeling Based Perirectal Fat Segmentation from CT Images. Lecture Notes in Computer Science, 2013, , 194-202.	1.0	1
136	Computer assisted decision making after portal imaging. , 2000, , 589-591.		1
137	Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure. Anticancer Research, 2017, 37, 6943-6946.	0.5	1
138	Gleason score and the risk of cause-specific and all-cause mortality following radiation with or without 6Âmonths of androgen deprivation therapy for men with unfavorable-risk prostate cancer. Journal of Radiation Oncology, 2016, 5, 301-308.	0.7	0
139	Measuring personal and functional changes in prostate cancer survivors: development and validation of the FADE: data from the TROG 03.04 RADAR trial. Psycho-Oncology, 2017, 26, 553-555.	1.0	0
140	Women who develop breast cancer. Medical Journal of Australia, 1994, 161, 507-507.	0.8	0